National Medical Insurance Administration: The first domestic new crown oral medication was adjusted for preliminary review through the medical insurance directory

The website of the National Medical Security Bureau on September 6th, in accordance ", The bureau's organizational force conducted preliminary review of the drug declaration data adjusted by the medical insurance category in 2022. From September 6th to September 12th, the drugs and related information that passed the preliminary form were publicized. The list information shows that the first domestic new crown oral medicine Azf's fixed table has been adjusted through the preliminary form of the national medical insurance catalog.

According to the National Medical Insurance Administration, the preliminary form review is preliminary review of whether the application of drugs that meet the application of the state medical insurance and drug catalog and the integrity of drug information.

In accordance with the "Interim Measures for the Management of Basic Medical Insurance Drugs", the national medical insurance and drug catalog adjustment is implemented to implement an enterprise application system. The National Medical Insurance Administration adjusted the work plan of the national medical insurance and drug catalogs to determine the application conditions and requirements, and each declared subject voluntarily declared. For preliminary review of drug declaration materials, on the one hand, the drugs that can be declared to meet the application conditions, on the other hand, review the integrity and standardization of the application information, and verify the authenticity of some materials according to the work needs of the work. It is conducive to ensuring that the information provided to experts is more accurate and complete. At the same time, in order to take the initiative to accept social supervision and ensure accurate form review results, publicize the drugs and some information that passed the results of preliminary review results, and welcome all sectors of society to put forward valuable opinions and suggestions. Considering that the economy of drugs mostly involves the company's secrets and core interests, the information related to the economy's application information submitted by the enterprise has not been announced.

The National Medical Insurance Bureau stated that the next step will further verify the relevant information based on the feedback received during the publicity period, determine the scope of the drug that finally passes the formal review, and announce it to the society. Subsequently, follow -up work will be promoted according to the plan, and follow -up work will be promoted.

Source 丨 National Medical Security Bureau website (copyright belongs to the original author, please contact delete if there is any infringement)

- END -